SrasV1, PascalFrancis, Corpus, bibRecord, 000537

Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection

Identifieur interne : 000537 ( PascalFrancis/Corpus ); précédent : 000536; suivant : 000538

Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection

Auteurs : Yao-Hsu Yang ; Yu-Hui Huang ; Ya-Hui Chuang ; Chung-Min Peng ; Li-Chieh Wang ; Yu-Tsan Lin ; Bor-Luen Chiang

Source :

Journal of medical virology [ 0146-6615 ] ; 2005.

RBID : Pascal:06-0155588

Descripteurs français

Pascal (Inist)
- Homme, Virus syndrome respiratoire aigu sévère, Autoanticorps, Cellule épithéliale, Cellule endothéliale, Cytotoxicité, Autoimmunité, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Autoantibody, Autoimmunity, Cytotoxicity, Endothelial cell, Epithelial cell, Human, Severe acute respiratory syndrome, Severe acute respiratory syndrome virus.

Abstract

The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0146-6615`
A02	`01`			`@0 JMVIDB`
A03		`1`		`@0 J. med. virol.`
A05				`@2 77`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection`
A11	`01`	`1`		`@1 YANG (Yao-Hsu)`
A11	`02`	`1`		`@1 HUANG (Yu-Hui)`
A11	`03`	`1`		`@1 CHUANG (Ya-Hui)`
A11	`04`	`1`		`@1 PENG (Chung-Min)`
A11	`05`	`1`		`@1 WANG (Li-Chieh)`
A11	`06`	`1`		`@1 LIN (Yu-Tsan)`
A11	`07`	`1`		`@1 CHIANG (Bor-Luen)`
A14	`01`			`@1 Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University @2 Taipei @3 TWN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 1-7`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17422 @5 354000132453040010`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 34 ref.`
A47	`01`	`1`		`@0 06-0155588`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medical virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.
C02	`01`	`X`		`@0 002A05C10`
C02	`02`	`X`		`@0 002B05C02J`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Autoanticorps @5 05`
C03	`03`	`X`	`ENG`	`@0 Autoantibody @5 05`
C03	`03`	`X`	`SPA`	`@0 Autoanticuerpo @5 05`
C03	`04`	`X`	`FRE`	`@0 Cellule épithéliale @5 06`
C03	`04`	`X`	`ENG`	`@0 Epithelial cell @5 06`
C03	`04`	`X`	`SPA`	`@0 Célula epitelial @5 06`
C03	`05`	`X`	`FRE`	`@0 Cellule endothéliale @5 07`
C03	`05`	`X`	`ENG`	`@0 Endothelial cell @5 07`
C03	`05`	`X`	`SPA`	`@0 Célula endotelial @5 07`
C03	`06`	`X`	`FRE`	`@0 Cytotoxicité @5 08`
C03	`06`	`X`	`ENG`	`@0 Cytotoxicity @5 08`
C03	`06`	`X`	`SPA`	`@0 Citotoxicidad @5 08`
C03	`07`	`X`	`FRE`	`@0 Autoimmunité @5 14`
C03	`07`	`X`	`ENG`	`@0 Autoimmunity @5 14`
C03	`07`	`X`	`SPA`	`@0 Autoinmunidad @5 14`
C03	`08`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 15`
C03	`08`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 15`
C03	`08`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 15`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 13`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 13`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 13`
C07	`06`	`X`	`FRE`	`@0 Virose`
C07	`06`	`X`	`ENG`	`@0 Viral disease`
C07	`06`	`X`	`SPA`	`@0 Virosis`
C07	`07`	`X`	`FRE`	`@0 Infection`
C07	`07`	`X`	`ENG`	`@0 Infection`
C07	`07`	`X`	`SPA`	`@0 Infección`
C07	`08`	`X`	`FRE`	`@0 Poumon pathologie @5 16`
C07	`08`	`X`	`ENG`	`@0 Lung disease @5 16`
C07	`08`	`X`	`SPA`	`@0 Pulmón patología @5 16`
N21				`@1 093`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0155588 INIST
ET :	Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection
AU :	YANG (Yao-Hsu); HUANG (Yu-Hui); CHUANG (Ya-Hui); PENG (Chung-Min); WANG (Li-Chieh); LIN (Yu-Tsan); CHIANG (Bor-Luen)
AF :	Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University/Taipei/Taïwan (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2005; Vol. 77; No. 1; Pp. 1-7; Bibl. 34 ref.
LA :	Anglais
EA :	The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.
CC :	002A05C10; 002B05C02J
FD :	Homme; Virus syndrome respiratoire aigu sévère; Autoanticorps; Cellule épithéliale; Cellule endothéliale; Cytotoxicité; Autoimmunité; Syndrome respiratoire aigu sévère
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie
ED :	Human; Severe acute respiratory syndrome virus; Autoantibody; Epithelial cell; Endothelial cell; Cytotoxicity; Autoimmunity; Severe acute respiratory syndrome
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease
SD :	Hombre; Severe acute respiratory syndrome virus; Autoanticuerpo; Célula epitelial; Célula endotelial; Citotoxicidad; Autoinmunidad; Síndrome respiratorio agudo severo
LO :	INIST-17422.354000132453040010
ID :	06-0155588

Links to Exploration step

Pascal:06-0155588

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection</title>
<author><name sortKey="Yang, Yao Hsu" sort="Yang, Yao Hsu" uniqKey="Yang Y" first="Yao-Hsu" last="Yang">Yao-Hsu Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Yu Hui" sort="Huang, Yu Hui" uniqKey="Huang Y" first="Yu-Hui" last="Huang">Yu-Hui Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuang, Ya Hui" sort="Chuang, Ya Hui" uniqKey="Chuang Y" first="Ya-Hui" last="Chuang">Ya-Hui Chuang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng, Chung Min" sort="Peng, Chung Min" uniqKey="Peng C" first="Chung-Min" last="Peng">Chung-Min Peng</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wang, Li Chieh" sort="Wang, Li Chieh" uniqKey="Wang L" first="Li-Chieh" last="Wang">Li-Chieh Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Yu Tsan" sort="Lin, Yu Tsan" uniqKey="Lin Y" first="Yu-Tsan" last="Lin">Yu-Tsan Lin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chiang, Bor Luen" sort="Chiang, Bor Luen" uniqKey="Chiang B" first="Bor-Luen" last="Chiang">Bor-Luen Chiang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0155588</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0155588 INIST</idno>
<idno type="RBID">Pascal:06-0155588</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000537</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection</title>
<author><name sortKey="Yang, Yao Hsu" sort="Yang, Yao Hsu" uniqKey="Yang Y" first="Yao-Hsu" last="Yang">Yao-Hsu Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Yu Hui" sort="Huang, Yu Hui" uniqKey="Huang Y" first="Yu-Hui" last="Huang">Yu-Hui Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chuang, Ya Hui" sort="Chuang, Ya Hui" uniqKey="Chuang Y" first="Ya-Hui" last="Chuang">Ya-Hui Chuang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng, Chung Min" sort="Peng, Chung Min" uniqKey="Peng C" first="Chung-Min" last="Peng">Chung-Min Peng</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wang, Li Chieh" sort="Wang, Li Chieh" uniqKey="Wang L" first="Li-Chieh" last="Wang">Li-Chieh Wang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lin, Yu Tsan" sort="Lin, Yu Tsan" uniqKey="Lin Y" first="Yu-Tsan" last="Lin">Yu-Tsan Lin</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chiang, Bor Luen" sort="Chiang, Bor Luen" uniqKey="Chiang B" first="Bor-Luen" last="Chiang">Bor-Luen Chiang</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medical virology</title>
<title level="j" type="abbreviated">J. med. virol.</title>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autoantibody</term>
<term>Autoimmunity</term>
<term>Cytotoxicity</term>
<term>Endothelial cell</term>
<term>Epithelial cell</term>
<term>Human</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Autoanticorps</term>
<term>Cellule épithéliale</term>
<term>Cellule endothéliale</term>
<term>Cytotoxicité</term>
<term>Autoimmunité</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0146-6615</s0>
</fA01>
<fA02 i1="01"><s0>JMVIDB</s0>
</fA02>
<fA03 i2="1"><s0>J. med. virol.</s0>
</fA03>
<fA05><s2>77</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>YANG (Yao-Hsu)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HUANG (Yu-Hui)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHUANG (Ya-Hui)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PENG (Chung-Min)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WANG (Li-Chieh)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LIN (Yu-Tsan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHIANG (Bor-Luen)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University</s1>
<s2>Taipei</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1-7</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17422</s2>
<s5>354000132453040010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>34 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0155588</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medical virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Autoanticorps</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Autoantibody</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Autoanticuerpo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cellule épithéliale</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Epithelial cell</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Célula epitelial</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cellule endothéliale</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Endothelial cell</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Célula endotelial</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cytotoxicité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cytotoxicity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Citotoxicidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Autoimmunité</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Autoimmunity</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Autoinmunidad</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>16</s5>
</fC07>
<fN21><s1>093</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0155588 INIST</NO>
<ET>Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection</ET>
<AU>YANG (Yao-Hsu); HUANG (Yu-Hui); CHUANG (Ya-Hui); PENG (Chung-Min); WANG (Li-Chieh); LIN (Yu-Tsan); CHIANG (Bor-Luen)</AU>
<AF>Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University/Taipei/Taïwan (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of medical virology; ISSN 0146-6615; Coden JMVIDB; Etats-Unis; Da. 2005; Vol. 77; No. 1; Pp. 1-7; Bibl. 34 ref.</SO>
<LA>Anglais</LA>
<EA>The severe acute respiratory syndrome (SARS) is caused by infection with the SARS-associated coronavirus (SARS-CoV) and characterized by severe pulmonary inflammation and fibrosis. In this study, the development of autoantibodies against human epithelial cells and endothelial cells in patients with SARS at different time periods (the first week: phase I, 1 month after the disease onset: phase II/phase III) were investigated. Antibodies in sera of patients and healthy controls against: (1) A549 human pulmonary epithelial cell-line, (2) human umbilical venous endothelial cells (HUVEC), (3) primary human pulmonary endothelial cells (HPEC) were detected by cell-based ELISA and indirect immunofluorescence staining. The results revealed that serum levels of IgG anti-A549 cells antibodies, IgG anti-HUVEC antibodies, and IgM anti-HPEC antibodies were significantly higher in SARS patients at phase II/phase III than those in healthy controls. Sera from SARS patients at phase II/ phase III could mediate complement dependent cytotoxicity against some A549 cells and HPEC. It is concluded that some autoantibodies against human epithelial cells and endothelial cells would be developed after SARS-CoV infection and this phenomenon may indicate post-infectious cellular injury and also induce SARS-induced immunopathology.</EA>
<CC>002A05C10; 002B05C02J</CC>
<FD>Homme; Virus syndrome respiratoire aigu sévère; Autoanticorps; Cellule épithéliale; Cellule endothéliale; Cytotoxicité; Autoimmunité; Syndrome respiratoire aigu sévère</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie</FG>
<ED>Human; Severe acute respiratory syndrome virus; Autoantibody; Epithelial cell; Endothelial cell; Cytotoxicity; Autoimmunity; Severe acute respiratory syndrome</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease</EG>
<SD>Hombre; Severe acute respiratory syndrome virus; Autoanticuerpo; Célula epitelial; Célula endotelial; Citotoxicidad; Autoinmunidad; Síndrome respiratorio agudo severo</SD>
<LO>INIST-17422.354000132453040010</LO>
<ID>06-0155588</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000537 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000537 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0155588
   |texte=   Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection

Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri